Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death

Abstract Most patients with advanced prostate cancer (PCa) initially respond well to androgen deprivation therapy (ADT) with antiandrogens, but most of them eventually become resistant to ADT. Here, we found that the antiandrogen Enzalutamide-resistant (EnzR) PCa cells can be suppressed by hyper-phy...

Full description

Bibliographic Details
Main Authors: Zhendong Xiang, Yin Sun, Bosen You, Meng Zhang, Chiping Huang, Junfeng Yu, Xiangyun You, Denglong Wu, Chawnshang Chang
Format: Article
Language:English
Published: Nature Publishing Group 2021-01-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-020-03321-z